Vortioxetine is marketed under several brand names, including Trintellix and Brintellix [1]. While "fonksera" is mentioned in relation to vortioxetine, it does not appear to be a currently recognized or marketed brand name for the drug [1].
When did vortioxetine first become available?
Vortioxetine was first approved by the U.S. Food and Drug Administration (FDA) in October 2013 under the brand name Trintellix [1]. Prior to that, it was approved in Europe in 2013 as Brintellix [1].
What is vortioxetine used to treat?
Vortioxetine is prescribed for the treatment of major depressive disorder (MDD) in adults [1].
How does vortioxetine work?
Vortioxetine is classified as a serotonin modulator and stimulator (SMS) [1]. Its precise mechanism of action in treating depression is not fully understood, but it is believed to involve modulating serotonin neurotransmission [1]. It affects multiple serotonin receptors, including acting as an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors, and an antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors [1].
What are the common side effects of vortioxetine?
Common side effects associated with vortioxetine include nausea, constipation, vomiting, dry mouth, dizziness, and abnormal dreams [1].
When does the patent for vortioxetine expire?
The patent protection for vortioxetine, and consequently the potential for generic versions, is a complex area. Patent expiry dates can vary based on specific patents, patent challenges, and market exclusivity provisions. Information on specific patent expiry timelines for vortioxetine can be found on resources like DrugPatentWatch.com [2].
Who manufactures vortioxetine?
Vortioxetine is manufactured by Takeda Pharmaceutical Company and Lundbeck [1].